Provided by Tiger Fintech (Singapore) Pte. Ltd.

CureVac B.V.

5.39
-0.0150-0.28%
Volume:275.99K
Turnover:1.49M
Market Cap:1.21B
PE:5.35
High:5.40
Open:5.38
Low:5.37
Close:5.40
52wk High:5.72
52wk Low:2.37
Shares:225.17M
Float Shares:125.87M
Volume Ratio:1.13
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.01
EPS(LYR):0.7483
ROE:40.22%
ROA:23.77%
PB:1.78
PE(LYR):7.20

Loading ...

Curevac Cut to Hold From Buy by Jefferies

Dow Jones
·
Jun 13

U.S. RESEARCH ROUNDUP-Darden Restaurants, EOG Resources, Oracle

Reuters
·
Jun 13

CureVac downgraded to Hold from Buy at Jefferies

TIPRANKS
·
Jun 13

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Cardinal Health, Adobe

Reuters
·
Jun 13

Nasdaq Moves Higher; Oracle Shares Jump After Upbeat Q4 Results

Benzinga
·
Jun 13

CureVac Up Over 38%, on Pace for Record Percent Increase -- Data Talk

Dow Jones
·
Jun 12

Stock Track | CureVac Soars 34% on BioNTech's $1.25 Billion Acquisition Deal

Stock Track
·
Jun 12

Top Premarket Gainers

MT Newswires Live
·
Jun 12

Stock Track | CureVac Shares Soar 29% Pre-market on $1.25 Billion BioNTech Acquisition Deal

Stock Track
·
Jun 12

Stock Track | CureVac Soars 29% in Pre-market as BioNTech Announces $1.25 Billion Acquisition

Stock Track
·
Jun 12

Biontech Announces Strategic Transaction To Acquire Curevac In Public Exchange Offer

Reuters
·
Jun 12

CureVac Soars 30% as BioNTech to Buy CureVac for $1.25 Billion to Boost Cancer Arm

Bloomberg
·
Jun 12

BioNTech to Acquire CureVac in All-Stock Deal

MT Newswires Live
·
Jun 12

BioNTech to acquire CureVac in public exchange offer

TIPRANKS
·
Jun 12

BioNTech SE Acquires CureVac to Boost mRNA-Based Cancer Immunotherapy Development

Reuters
·
Jun 12

CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly

Reuters
·
May 23

CureVac NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 22

Stock Track | CureVac Stock Plummets 5.14% Ahead of Expected Q1 Earnings Report

Stock Track
·
May 21

Stock Track | CureVac Soars 5.17% as Strong Cash Position Outweighs Revenue Decline

Stock Track
·
May 20

Stock Track | CureVac Soars 5.17% on Strong Cash Position and Extended Runway Despite Q1 Revenue Decline

Stock Track
·
May 20